The Parkinsonism/dementia complex of Guam (PDC) bears significant clinical similarities to conventional Parkinson's Disease, and to conventional Alzheimer's disease. As is the case with the conventional disorders, the cause of PDC is unknown. The unusual geographical clustering of PDC and the inability to analyze PDC in terms of conventional patterns of inheritance have lead to the hypothesis that PDC is the result of an environmental toxin (e.g. cycasin) although a pathogenic link has not been proven. This laboratory and other laboratories have demonstrated specific abnormalities of the mitochondrial electron transport chain in both Parkinson's disease and Alzheimer's disease. A significant body of evidence suggests these defects have pathogenic significance. We have demonstrated that PDC patients have similar mitochondrial defects which may be pathogenic. This project will pursue the hypothesis that PDC is characterized by specific mitochondrial defects and that the mitochondrial genome is important in producing these defects. Previous data dealing with PDC will be expanded to include studies of the mitochondrial electron transport chain in Guam motor-neuron disease patients. The occurrence of these specific biochemical defects will be investigated in autopsy samples from brain, myocardium, and skeletal muscle. In order to evaluate the hypothesized role of the mitochondrial genome in the production of these biochemical lesions, mitochondrial DNA will be transfered from patient and control platelets into recently prepared mitochondrial DNA deficient host cell lines and the resulting biochemical phenotype will be assayed. Positive results will indicate involvement of the Mitochondrial genome in PDC. These experiments will be done with platelets from Guam patients and controls and with equivalent samples from the San Diego Chamorro cohort. Finally, we will evaluate the effects of various putative pathogenic toxins on mitochondrial electron transport chain activities rat brain with the goal of determining whether or not any of these toxins can produce the biochemical defects observed in these patients. This project will extend early and very important observations about potential pathogenic mechanisms in PDC/motorneuron disease, provide data on previously unexplored biochemical actions of potential pathogenic toxins, and evaluate a novel hypothesis regarding cause of this disorder. This project will also reinforce the observed biochemical and genetic.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG014382-04
Application #
6299379
Study Section
Project Start
2000-03-01
Project End
2001-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
2000
Total Cost
$423,146
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dombroski, Beth A; Galasko, Douglas R; Mata, Ignacio F et al. (2013) C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol 70:742-5
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Lee, Virginia M-Y; Brunden, Kurt R; Hutton, Michael et al. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437
Yu, Chang-En; Bird, Thomas D; Bekris, Lynn M et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161-70
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Snyder, L R; Cruz-Aguado, R; Sadilek, M et al. (2009) Lack of cerebral bmaa in human cerebral cortex. Neurology 72:1360-1
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38

Showing the most recent 10 out of 53 publications